Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases.

Our products incorporate a proprietary “sialic switch” technology to improve the anti-inflammatory properties of antibodies.

Virdante’s investors include: Clarus Ventures; Venrock; Thomas, McNerney & Partners; MedImmune Ventures; Biogen Idec New Ventures; and Osage Partners.

Virdante is located in Cambridge, MA.